CS-8958 - A Phase I, Double-Blind, Placebo-Controlled, Ascending Single Inhaled Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2016
At a glance
- Drugs Laninamivir (Primary)
- Indications Influenza virus infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Aviragen Therapeutics; Biota Holdings
- 11 Jan 2009 Status changed from active, no longer recruiting to completed, according to the clinicaltrials.gov record.
- 17 Dec 2007 Status changed from recruiting to in progress according to ClinicalTrials.gov.
- 26 Apr 2007 Status changed from initiated